Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 11,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total transaction of $509,080.00. Following the sale, the insider now directly owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Gary Charles Robb also recently made the following trade(s):

• On Monday, August 26th, Gary Charles Robb sold 3,101 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71.

Corcept Therapeutics Stock Performance

Shares of CORT traded up $0.47 during trading hours on Tuesday, reaching $46.75. The stock had a trading volume of 1,152,218 shares, compared to its average volume of 1,200,508. The stock has a market capitalization of $4.87 billion, a PE ratio of 44.10 and a beta of 0.45. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $47.71. The company’s 50-day moving average is $36.63 and its two-hundred day moving average is $30.93.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Monday, July 29th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.23 by $0.09. The firm had revenue of $163.80 million during the quarter, compared to the consensus estimate of $155.14 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period last year, the company earned $0.25 earnings per share. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of Corcept Therapeutics by 199.0% during the first quarter. BNP Paribas Financial Markets now owns 211,592 shares of the biotechnology company’s stock valued at $5,330,000 after acquiring an additional 140,815 shares during the last quarter. Quantedge Capital Pte Ltd acquired a new position in Corcept Therapeutics during the 4th quarter worth about $8,066,000. Oak Ridge Investments LLC acquired a new position in Corcept Therapeutics during the 2nd quarter worth about $984,000. State Board of Administration of Florida Retirement System grew its position in shares of Corcept Therapeutics by 190.0% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 66,866 shares of the biotechnology company’s stock valued at $1,684,000 after buying an additional 43,809 shares during the last quarter. Finally, US Bancorp DE increased its stake in shares of Corcept Therapeutics by 6,252.3% in the first quarter. US Bancorp DE now owns 25,282 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 24,884 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CORT has been the topic of a number of research analyst reports. Truist Financial raised their target price on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler raised their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, September 18th. HC Wainwright boosted their target price on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $56.50.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.